Ute Moll, MD, MS
Professor
Vice Chair for Experimental Pathology
Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691
Tel: (631) 444-2459
Fax: (631) 444-3424
Email: Ute.Moll@stonybrookmedicine.edu
Clinical Practice:
Dr. Moll currently participates in the autopsy program at Stony Brook University Hospital.
Education: | |||
Institution & Location | Degree | Year(s) | Field of Study |
University of Ulm, Germany | MS | 1980 | Biology |
University of Ulm, Germany | MD | 1985 | Medicine |
Research Summary:
Positions and Employment:
1986-1989 | Resident, Anatomic & Clinical Pathology, Stony Brook University |
1989-1990 | Postdoctoral Research Fellow, Stony Brook University, lab of Dr. James Quigley |
1991-1992 | Postdoctoral Research Fellow, Princeton University, lab of Dr. Arnold J. Levine |
1992-1997 | Assistant Professor, Department of Pathology, Stony Brook University |
1997-2001 | Associate Professor, Department of Pathology, Stony Brook University |
2002-present | Full Professor, Department of Pathology, Stony Brook University |
2009-present | Vice Chair, Research, Department of Pathology Stony Brook University |
2012-present | Co-Director, Stem Cell Analysis Core, Stony Brook Stem Cell Facility |
Other
Experience and Professional Memberships (selected):
1988-1989 | Chief Resident, Department of Pathology, Stony Brook University |
2007-present | Guest Professor, Department of Molecular Oncology, University of Göttingen, Germany |
Honors (selected):
2006 | Baldwin Award for Cancer Research, Stony Brook University |
2011 | Baldwin Award for Cancer Research, Stony Brook University |
2012 | Fusion Award, Stony Brook University |
2013 | Inaugural Excellence in Basic Research Award, School of Medicine, Stony Brook University |
2017 | Induction as Member, Association of American Physicians (AAP) |
2017 | SUNY Central Chancellor's Award for Excellence in Scholarship |
Selected publications (of total of 166):
- Schulz-Heddergott R, Stark N, Edmunds S, Li J, Conradi L, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM . Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Schulz-Heddergott et al., 2018, Cancer Cell 34, 298–314, August 13, 2018 ª 2018 Elsevier Inc. https://doi.org/10.1016/j.ccell.2018.07.004.
- Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S,
Roßmann L, Bastians H, Concin N, Moll
UM, Dobbelstein M (2017). Strong antitumor synergy between DNA
crosslinking and HSP90 inhibition causes massive premitotic DNA
fragmentation in ovarian cancer cells. Cell Death Differ 24(2):300-316.
- Nemajerova A*, Kramer D, et al. Bonn S, Takemaru
K-I, Moll UM* and Lizé M* (2016). TAp73 is a central
transcriptional regulator of airway multiciliogenesis. Genes & Development, 30(11):1300-12. Featured
on Journal Cover. Editorial by Napoli M,
Flores ER. Unifying the p73 knockout phenotypes: TAp73 orchestrates. multiciliogenesis. Genes Dev. 2016 Jun 1;30(11):1253-4
- Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J,
Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M (2015). microRNA-101 Suppresses Tumor
Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via
Targeting the Proteasome Assembly Factor POMP. Mol Cell,
59(2):243-57
- Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M (2015). MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness- Promoting Chromatin Modifications Independent of p53. Mol Cell, 61(1):68-83.
- Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M and Moll UM. (2015) Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment. Nature, 523(7560): 352-6.
- Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova
A, Dobbelstein M and Moll UM (2014).
TAp73
is essential for germ cell adhesion and maturation in testis. Journal
Cell Biology, 204 (7), 1173-1190. Featured in Journal’s Highlights. Featured in Asian J Androl (2014)16, 799-800.
- Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND and UM Moll (2014) p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. Cell Death Diff doi: 10.1038/cdd.2013.199.
- Dobbelstein M, and Moll UM (2014) Targeting tumor-supportive cellular machnineries in anticancer drug development. Nature Reviews Drug Discovery 13(2):179-96.
- Alexandrova E, Petrenko O,
Nemajerova A, Romano RA,Sinha S and Moll UM (2013). ΔNp63 is required for select routes of
reprogramming via multiple mechanisms. Cell Death Diff 20(12):1698-708.
- Vaseva
AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012).
p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell
149, 1536-1548. Featured as Cover story of the Cell
issue.
- Schulz R, Marchenko ND,
Holembowski, Dobbelstein M, Moll UM (2012). Inhibiting the HSP90 chaperone destabilizes MIF and thereby inhibits
breast tumor progressionJ Exp Med 209(2):275-289.
- Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M (2011). Endogenous
retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ
line of humans and great apes. PNAS 108(9): 3624-9. Featured in Science, Editor’s Choice vol 331, 18 Febr
2011, page 823. Highlighted in “This Week in PNAS” front section of issue Febr
15, 2011, 108 (7).
- Nemajerova A, Petrenko O, Trümper L, Palacios G, Moll UM (2010) Loss
of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J
Clin Invest 120(6):2070-80.
- Wolff S, Talos F, Palacios G, Beyer
U, Dobbelstein M, Moll UM (2009). The alpha/beta
carboxyterminal domains of p63 are required for skin and limb development. Cell
Death Diff 16(8):
1108-17.
- Flaminia Talos, Alice Nemajerova, Elsa R. Flores, Oleksi
Petrenko and Moll UM (2007). p73 maintains
the integrity of the genome and prevents rereplication. Mol Cell 27(4): 647-59.
- Marchenko ND, Wolff S, Erster S and Moll UM (2007). Monoubiquitylation
promotes mitochondrial p53 translocation. EMBO J 26(4):923-34.
- Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O
(2007). Impaired
DNA damage checkpoint response in MIF-deficient mice. EMBO
J, Feb 21;26(4) 987-97.
- Petrenko O and Moll
UM (2005). MIF Interferes with the Rb-E2F Pathway.
Mol
Cell 17(2): 225-36.
- Talos F, Petrenko O, Mena P and Moll UM (2005). Mitochondrially
Targeted p53 has Tumor Suppressor Activities In vivo. Cancer Res 65(21):1-11.
- Mihara M, Erster S, Zaika A,
Petrenko O, Chittenden T, Pancoska P, Moll
UM (2003). p53 has a direct apoptogenic role at the
mitochondria. Mol Cell 11(3): 577-90.
- Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 196(6): 765-80.